Introduction:
Myeloid sarcoma (MS), also known as chloroma or granulocytic sarcoma is
a condition characterized by abnormal proliferation of blast cells, from
one or more myeloid cell, and leads to a disruption in the structure of
tissues (1). Its incidence ranges from 2.5% to 8%. It is commonly
associated with subtypes of Acute Myeloid Leukemia (AML) such as M5a,
M5b, M4 and M2 (2). Myeloid sarcoma can affects various body parts
including lymph nodes, skin, soft tissues, testicles, bones, peritoneum
and gastrointestinal tract(3,4). It can occur either on its own or as
part of an AML relapse. The diagnosis is typically confirmed through
immunohistochemistry analysis of a sample taken from the area.
Unfortunately the prognosis of myeloid sarcoma is generally poor
especially when it is associated with an AML relapse.(5)